IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Toshiharu ARISHIMA et al.

Mail Stop: PCT

Serial No. NEW

Attorney Docket No. 2006 0961A

Filed December 24, 2004

LIPASE INHIBITOR

[Corresponding to PCT/JP2004/019360

Filed December 24, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

IJ	each U.S. Patent and U.S. Patent application publication;
	each reference previously cited in the international application PCT/; and/or
0	each reference previously cited in prior parent application Serial No.

1a. [X] This Information Disclosure Statement is submitted:

> within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b.	[] This	Information Disclosure Statement is submitted						
	e events of above paragraph 1a and prior to the mailing date of a final Office or a Notice of Allowance or an action which otherwise closes prosecution in the ion, and thus:							
	ne certification of paragraph 2 below is provided, or							
	(2) [] th	(2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.						
1c.	[] This Information Disclosure Statement is submitted:							
	e mailing date of a final Office Action or Notice of Allowance or action which se closes prosecution in the application, and prior to payment of the issue fee, and							
	the cert	the certification of paragraph 2 below is provided, and						
	the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.							
2.	It is hereby certified							
	a. []	that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or						
	b. []	that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.						

abandoned U.S. application, prior uses and/or sales, etc.) is requested.

3. []

Consideration of the following list of additional information (including any copending or

40/583382 AP3 Rec'd PCT/PTO 19 JUN 2006

4.	For each non-English language reference listed on the attached form PTO-1449, reference
	is made to:

- a. [] a full or partial English language translation submitted herewith,
- b. [X] a foreign patent office (International) search report (in the English language) submitted herewith (Attachment E),
- c. [] the concise explanation contained in the specification of the present application at page,
- d. [X] the concise explanation set forth in the attached English language abstract,
- e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [] A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Toshiharu ARISHIMA et al.

By

Matthew M. Jacob Registration No. 25,154

Attorney for Applicants

MJ/kes Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 June 19, 2006

						40	1502302			
. Sheet 1 c. 1		•	INFORMA	TION DISCLOSURE S	APARAC'	PCTPT	1 0 1111 200			
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE				ATTY DOCKET NO 2006_0961A	1	SERIAL NO. NEW	~ 9 0014500	'		
PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: June 19, 2006				APPLICANT Toshiharu ARISHIMA et al.						
				FILING DATE December 24, 2004		GROUP				
			U.	S. PATENT DOCUME	ITS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	AA									
	АВ									
	AC									
			FORE	EIGN PATENT DOCUM	ENTS	-	<u>,</u>			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO			
	AD	5-59392	03/1993	JP		<u> </u>	abstract			
	AE	2002-524612	08/2002	JP			corresponds to AF			
- <u>-</u> -	AF	00/15043	03/2000	wo			corresponds to AE			
	AG	2001-40387	02/2001	JP			corresponds to AH			
	АН	01/09272 A1	02/2001	wo			corresponds to AG			
	AI	1106681	08/1981	CA						
	AJ	2001-523714	11/2001	JP			corresponds to AK			
	AK	99/26619	06/1999	wo			corresponds to AJ			
· · · · · · · · · · · · · · · · · · ·	AL	2003-119150	04/2003	JP			abstract			
	AM	2002-188096	07/2002	JP			abstract			
	,	OTHER	DOCUMENT(S) (I	Including Author, Title,	Date, Pertinent Pages	, Etc.)				
	AN	Nakabo, Y. et al., "1,3-dicaproyl-2-stearoyl-glycerol", <i>Digestion & Absorption</i> , Vol. 14, No. 2, pp. 31 to 34 (1991).								
	AO	Softly, B. et al., "Composition of Representative SALATRIM Fat Preparations", <i>J. Agric. Food Chem.</i> , Vol. 42, pp. 461 to 467 (1994).								
	AP	Spener, F. et al., "The Intestinal Absorption of Glycerol Trioctadecenyl Ether", <i>Biochimica et Biophysica Acta</i> , Vol. 152, pp. 368 to 371 (1968).								
EXAMINER				DATE CONSIDERED						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.